에 대한 최신 뉴스 Hill & Smith (OTC:HSHPF) 주식

Hill & Smith PLC creates sustainable infrastructure and safe transport through innovation. It is organized into three main business divisions. Galvanizing Services increase the sustainability and maintenance-free life of steel products including structural steelwork, lighting, bridges, agricultural and other products for the industrial and infrastructure markets. Engineered Solutions supplies engineered steel and composite solutions for a wide range of infrastructure markets including energy generation and distribution, marine, rail, and housing. Roads & Security division supplies products and services to support road and highway infrastructure including temporary and permanent road safety barriers, renewable energy lighting and power solutions, and Intelligent Traffic Solutions.

HILL & SMITH HOLDINGS by Hill & Smith Holdings Plc.

Hill & Smith PLC

Armata Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ARMP#AMEX">ARMP</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.38) by 47.37 percent. This is a 71.01 percent increase over losses of $(0.69) per share from the same period last year. The company reported quarterly sales of $491.00 thousand which missed the analyst consensus estimate of $1.38 million by 64.42 percent. This is a 49.17 percent decrease over sales of $966.00 thousand the same period last year.

Earnings

Earnings Beats

Earnings Misses

News

ARMP

Armata Pharmaceuticals Q1 EPS $(0.20) Beats $(0.38) Estimate, Sales $491.00K Miss $1.38M Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for FY2026 Adj EPS of $2.75-$3.25 vs $3.41 analyst estimate. sees sales of $12.180 billion-$12.440 billion vs $12.41 billion analyst estimate.

Guidance

DXC Technology Sees FY2026 Adj EPS $2.75-$3.25 vs $3.41 Est; Sees Sales $12.180B-$12.440B vs $12.41B Est

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) is looking for Q1 Adj EPS of $0.55-$0.65 vs $0.77 analyst estimate. sees sales of $3.040 billion-$3.090 billion vs $3.12 billion analyst estimate.

DXC Technology Sees Q1 Adj EPS $0.55-$0.65 vs $0.77 Est; Sees Sales $3.040B-$3.090B vs $3.12B Est

SPACE

General

RKLB

NASA Selects Rocket Lab To Launch Aspera Mission To Study Galaxy Evolution

Okeanis Eco Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ECO#NYSE">ECO</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.24 by 50 percent. This is a 70.73 percent decrease over earnings of $1.23 per share from the same period last year. The company reported quarterly sales of $80.15 million which beat the analyst consensus estimate of $74.56 million by 7.49 percent. This is a 27.95 percent decrease over sales of $111.23 million the same period last year.

Okeanis Eco Tankers Q1 Adj. EPS $0.36 Beats $0.24 Estimate, Sales $80.15M Beat $74.56M Estimate

CSCO

Cisco Says EPS Guidance Includes Estimated Impact Of Tariffs Based On Current Trade Policy; AI Infrastructure Orders Surpassing Our $1B Target One Quarter Early

GEE Group Q2 Adj. EPS $(0.30), Sales $24.50M Down From $28.05M YoY

Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.12) by 25 percent. This is a 79.45 percent increase over losses of $(0.73) per share from the same period last year.

Inhibikase Therapeutics Q1 EPS $(0.15) Misses $(0.12) Estimate

WIIM

BNGO

Bionano Genomics shares are trading higher following better-than-expected Q1 reported financial results.

Eledon Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELDN#NASDAQ">ELDN</a>) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.30) by 73.33 percent. This is a 89.87 percent increase over losses of $(0.79) per share from the same period last year.

ELDN

Eledon Pharma Q1 EPS $(0.08) Beats $(0.30) Estimate

Gold miners&#8217; stocks, 2025&#8217;s standout performers, faced a sharp reversal this week as investor appetite for safe havens cooled following the U.S.-China trade truce, raising fresh doubts about the sustainability of<a href="https://www.benzinga.com/topic/gold-miners"> the sector&#8217;s explosive rally.</a>
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>)—a widely tracked proxy for gold mining stocks—plunged 9.6% over three sessions, marking its worst three-day performance since April 2022. 
The move was amplified by a 4.4% drop in gold prices, which now sit 9.2% below the all-time high of $3,500 per ounce reached on April 22.
Losses were broad-based within the GDX components. Newmont Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>), its largest holding, dropped 10% in just three days. Similar losses were recorded in Barrick Gold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOLD#NYSE">GOLD</a>) and Agnico Eagle Mines Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AEM#NYSE">AEM</a>).
The abrupt reversal comes as risk appetite surges globally, diminishing gold's appeal. The May 12 announcement of a 90-day U.S.-China tariff rollback helped lift equities and risk assets, reducing investor hedges in gold.
<h3 class="wp-block-heading">Technical Setups Signal Caution For Gold</h3>
Technical analysts are growing cautious. Bank of America technical analyst, Paul Ciana said the daily gold chart is showing signs of a potential double top pattern. 
He indicated that a close below $3,200 per ounce would increase the risk of a correction to the $2,900–$3,000 range during the second quarter.
From a fundamental view, David Morrison, senior market analyst at Trade Nation, observed that gold is consolidating around the lower end of its recent range. 
He flagged $3,200 as the first key support level. "It looks as if the path of least resistance may be down for gold, although much now depends on how staunchly the bulls can defend the $3,200 level," he said.
Nikos Tzabouras, senior market analyst at Tradu.com, said the trade truce buoyed market sentiment and reduced near-term demand for havens like gold. 
"Gold remains under pressure, with scope for further declines as risk appetite holds firm," he said, while cautioning that geopolitical uncertainty and central bank buying still support the longer-term case.
<h3 class="wp-block-heading">Seasonality Enters Choppy Phase</h3>
Seasonal trends may also be at play. Historically, gold posts strong gains in the first four months of the year, followed by a choppy stretch between mid-May and mid-July. In that two-month window, bullion has delivered positive returns just 42% of the time over the past decade.
This seasonal lull could compound downside pressure, especially if key support levels fail to hold.
Conclusion: Time to Take Some Chips Off the Table?
While gold miners have delivered strong year-to-date returns – with the GDX ETF up 30% through mid May. 
Yet, the combination of technical weakness, a seasonally soft window, and shifting macro tailwinds suggests a more cautious stance may be warranted in the short term. 
For investors sitting on large gains, this could be an opportune moment to lock in profits—or at least tighten risk controls—while waiting for clearer signals.
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45410216/cruises-set-sail-ahead-of-summer-boom-these-3-sp-500-stocks-show-strongest-late-may-seasonality">Cruises Set Sail Ahead Of Summer Boom: These 3 S&amp;P 500 Stocks Show Strongest Late-May Seasonality</a><span class="author" style="box-sizing: border-box; border: 0px solid rgb(229, 231, 235); --tw-scale-x: 1; --tw-scale-y: 1; --tw-pan-x: ; --tw-pan-y: ; --tw-pinch-zoom: ; --tw-scroll-snap-strictness: proximity; --tw-gradient-from-position: ; --tw-gradient-via-position: ; --tw-gradient-to-position: ; --tw-ordinal: ; --tw-slashed-zero: ; --tw-numeric-figure: ; --tw-numeric-spacing: ; --tw-numeric-fraction: ; --tw-ring-inset: ; --tw-ring-offset-width: 0px; --tw-ring-offset-color: #fff; --tw-ring-color: rgba(59,130,246,.5); --tw-ring-offset-shadow: 0 0 #0000; --tw-ring-shadow: 0 0 #0000; --tw-shadow: 0 0 #0000; --tw-shadow-colored: 0 0 #0000; --tw-blur: ; --tw-brightness: ; --tw-contrast: ; --tw-grayscale: ; --tw-hue-rotate: ; --tw-invert: ; --tw-saturate: ; --tw-sepia: ; --tw-drop-shadow: ; --tw-backdrop-blur: ; --tw-backdrop-brightness: ; --tw-backdrop-contrast: ; --tw-backdrop-grayscale: ; --tw-backdrop-hue-rotate: ; --tw-backdrop-invert: ; --tw-backdrop-opacity: ; --tw-backdrop-saturate: ; --tw-backdrop-sepia: ; --tw-contain-size: ; --tw-contain-layout: ; --tw-contain-paint: ; --tw-contain-style: ;"></li>
</ul>
Photo: Shutterstock

Analyst Color

Equities

Large Cap

Macro Economic Events

Sector ETFs

Econ #s

Economics

Analyst Ratings

Tech

ETFs

Market Vectors ETF Trust Market Vectors Gold Miners

GOLD

Gold Miners Slammed By US-China Trade Truce: Is It Time To Take Profit?

BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.39) by 51.28 percent. This is a 56.3 percent increase over losses of $(1.35) per share from the same period last year.

BCDA

BioCardia Q1 EPS $(0.59) Misses $(0.39) Estimate

Conifer Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNFR#NASDAQ">CNFR</a>) reported quarterly losses of $(0.30) per share. This is a 372.73 percent decrease over earnings of $0.11 per share from the same period last year. The company reported $10.31 million in sales this quarter. This is a 38.92 percent decrease over sales of $16.89 million the same period last year.

CNFR

Conifer Holdings Q1 Adj. EPS $(0.30) Down From $0.11 YoY, Sales $10.31M Down From $16.89M YoY

BOOT

Boot Barn Holdings shares are trading higher after the company issued Q1 guidance with its midpoint above estimates and announced a $200 million share repurchase program.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

Canaan For April Mined 87 Bitcoins

Zentalis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZNTL#NASDAQ">ZNTL</a>) reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.63) by 6.35 percent. This is a 578.57 percent decrease over earnings of $0.14 per share from the same period last year.

ZNTL

Zentalis Pharma Q1 EPS $(0.67) Misses $(0.63) Estimate

DXC Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DXC#NYSE">DXC</a>) reported quarterly earnings of $0.84 per share which beat the analyst consensus estimate of $0.77 by 9.09 percent. This is a 13.4 percent decrease over earnings of $0.97 per share from the same period last year. The company reported quarterly sales of $3.17 billion which beat the analyst consensus estimate of $3.13 billion by 1.16 percent. This is a 6.41 percent decrease over sales of $3.39 billion the same period last year.

DXC Technology Q4 Adj. EPS $0.84 Beats $0.77 Estimate, Sales $3.17B Beat $3.13B Estimate

CRWV

CoreWeave Q1 Adj. EPS $(0.599) May Not Compare To $(0.12) Estimate

Electrovaya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) FY2025 Revenue expected to be more than $60.00M vs $67.92M Est

ELVA

Electrovaya FY2025  Revenue expected to be more than $60.00M vs $67.92M Est

GCT Semiconductor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 600 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $496.00 thousand which missed the analyst consensus estimate of $1.87 million by 73.53 percent. This is a 84.81 percent decrease over sales of $3.27 million the same period last year.

Comments

Hill & Smith

뉴스

에 대한 최신 뉴스 Hill & Smith (OTC:HSHPF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌